NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
Clinical Trials
84 trialsNCT07458659 2026-03-09
CART-BCMA
Chulalongkorn University
Phase EARLY_PHASE1 Not yet recruiting
NCT07416682 2026-02-25
CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07429721 2026-02-24
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Not yet recruiting
NCT07399444 2026-02-10
LB2505-0001
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT05093335 2026-02-05
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06663046 2026-01-20
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07185490 2026-01-20
IASO104
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT07336823 2026-01-13
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT07322159 2026-01-07
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT06385652 2026-01-06
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT04370483 2026-01-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Phase EARLY_PHASE1 Active not recruiting
NCT05560399 2026-01-02
CC-220
Icahn School of Medicine at Mount Sinai
Phase EARLY_PHASE1 Active not recruiting
NCT03631043 2025-12-19
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT07294625 2025-12-19
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Recruiting
NCT07249073 2025-11-25
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT07185477 2025-09-22
QLS32015
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT04862676 2025-09-10
Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
University of Rochester
Phase EARLY_PHASE1 Completed
NCT07101705 2025-09-09
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06986434 2025-09-03
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT06988059 2025-08-01
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT07077330 2025-07-22
CAR19BCMA
Chinese PLA General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06976437 2025-07-10
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
Phase EARLY_PHASE1 Recruiting
NCT06717113 2025-06-06
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT06691685 2025-03-25
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT05302648 2025-01-03
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Active not recruiting
NCT06209606 2024-12-17
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
Phase EARLY_PHASE1 Recruiting
NCT06732232 2024-12-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT06718270 2024-12-12
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06407947 2024-06-12
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06379451 2024-04-23
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Changzhou No.2 People's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06359509 2024-04-11
Study of SYS6020 in BCMA-positive Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Not yet recruiting
NCT05013437 2024-04-02
AHCT
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT06298266 2024-03-07
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT05840107 2024-02-13
Study of FasT CAR-T GC012F Injection NDMM Patients
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Unknown
NCT05643248 2023-10-31
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
Nanexa AB
Phase EARLY_PHASE1 Completed
NCT06067581 2023-10-05
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT03591614 2023-08-18
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT04211259 2023-08-07
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Unknown
NCT03272633 2023-06-26
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Terminated
NCT03371420 2023-04-18
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT05655676 2022-12-19
89Zr-labeled NY008 PET Imaging in Patients
Affiliated Hospital of Jiangnan University
Phase EARLY_PHASE1 Unknown
NCT05652530 2022-12-15
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Shenzhen Pregene Biopharma Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02851056 2022-11-14
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT05016778 2022-11-01
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT05478343 2022-07-28
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05430945 2022-06-24
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Unknown
NCT04657861 2022-05-09
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Recruiting